PneumoWave, a Glasgow, Scotland, UK-based digital health company, raised £7.5M in Series A funding.
The round was led by Scottish National Investment Bank, Scottish Enterprise, IIG, Equity Gap, Alba Equity, and Mark Bamforth of Thairm Bio.
The company intends to use the funds to enable clinical validation and regulatory submission of its platform.
Led by CEO Dr Bruce Henderson, PneumoWave is advancing a biosensor technology platform for remote wireless diagnosing and monitoring potentially fatal respiratory changes in high-risk patient groups. A wearable biosensor alerts carers and emergency medical services. The company aims to reduce the devastating socioeconomic impact of drug overdose, now the leading cause of accidental death in most developed countries.
PneumoWave’s technology is being developed as part of an international research program in collaboration with the University of Dundee, University of Glasgow, King’s College London, and NRCH and Department of Health in Victoria, Australia.
FinSMEs
12/01/2023